Background: Anaplastic thyroid carcinoma (ATC) is among the most lethal human malignancies, accounting for a disproportionate number of thyroid cancer-related deaths despite constituting less than 2% of all thyroid cancers. Historically regarded as universally fatal, with a median survival of only 3–6 months, the management of ATC has undergone a remarkable transformation over the past several decades.
Summary: Early treatment strategies in the mid-20th century relied primarily on palliative surgery and radiotherapy, offering minimal survival benefit. The late 20th century saw the emergence of multimodal therapy combining surgery, external beam radiation, and cytotoxic chemotherapy (doxorubicin, taxanes), which improved locoregional control but failed to significantly impact the high rate of distant metastases. The pivotal turning point arrived with advances in molecular biology, revealing critical oncogenic drivers—most notably BRAF V600E mutations in up to 45% of cases, as well as TERT, RAS, PIK3CA, TP53 alterations, and rare RET/NTRK fusions. This understanding catalysed the development of targeted therapies. The landmark FDA approval of the BRAF inhibitor dabrafenib combined with the MEK inhibitor trametinib in 2018 for BRAF V600E-mutated ATC fundamentally altered the therapeutic paradigm, demonstrating unprecedented response rates (≈70%), durable survival benefits (1-year survival ≈80%), and enabling neoadjuvant conversion of unresectable tumours. Subsequently, immunotherapy (anti-PD-1/PD-L1 agents), next-generation sequencing-guided personalised medicine, and combination strategies have become integral components of modern management.
Conclusion: The evolution of ATC management reflects a dramatic transition from nihilistic palliation to molecularly guided precision oncology. While stage IVC disease remains a formidable challenge, the incorporation of targeted therapy and immunotherapy has provided the first real hope for improved outcomes. This review traces this historical evolution, highlighting key milestones, current standards, and future directions.
Thyroid malignancies are increasing in frequency, yet anaplastic thyroid carcinoma (ATC) remains a rare but devastating entity. Accounting for only 1–2% of all thyroid cancers, ATC is responsible for up to 50% of thyroid cancer-related deaths.1,2 Patients typically present in their 6th to 7th decade with a rapidly enlarging, hard neck mass often associated with dysphagia, dyspnoea, hoarseness from recurrent laryngeal nerve invasion, and distant metastases (most commonly to lung, bone, and brain) in over 40% at the time of diagnosis.3,4
By definition, all ATCs are stage IV (American Joint Committee on Cancer, 8th edition: IVA, intrathyroidal; IVB, extrathyroidal extension; IVC, distant metastases).5 Historically, median survival ranged from 3 to 6 months, with a 1-year survival of only about 20%.6,7 For decades, therapeutic nihilism prevailed, and management was largely palliative.
However, the last two decades have witnessed a paradigm shift. The convergence of enhanced multidisciplinary care, sophisticated radiotherapy techniques (intensity-modulated radiotherapy, IMRT) and, most importantly, the elucidation of the ATC molecular landscape, has ushered in the era of precision oncology. This review analyses the historical evolution of ATC management, from early surgical palliation to modern targeted and immunotherapeutic approaches.
Historical Evolution of ATC Management [Fig. 1]
The Early Era (1950–1980): Surgery and Palliation
In the mid-20th century, treatment options were extremely limited. Surgery was the primary modality, but most patients presented with unresectable disease. Ultra -radical resections (e.g., with laryngectomy or esophagectomy) were associated with prohibitive morbidity without survival benefit. Radiotherapy was used palliatively for airway obstruction or pain, and chemotherapy was largely ineffective. The immediate causes of death were often asphyxiation from local progression or pulmonary metastases.4,8
The Era of Multimodality Therapy (1980–2010)
Recognition that single-modality therapy was futile led to combined approaches. The 2012 American Thyroid Association (ATA) guidelines formalised a multidisciplinary strategy: rapid diagnosis, airway assessment, stage-based planning, and a combination of surgery (R0/R1 resection when feasible), postoperative external beam radiotherapy (EBRT) (dose >40-45 Gy, preferably IMRT), and concurrent chemotherapy.1 Doxorubicin was the most studied agent, followed by platinum compounds and taxanes (paclitaxel, docetaxel).9 – 11
Studies from this era demonstrated improved locoregional control (≈70-80%) and extended median survival in stage IVA/B patients from approximately 3 months (surgery alone) to 12-25 months (multimodal therapy).12,13 However, distant metastatic disease remained the primary cause of failure, and outcomes for stage IVC patients remained dismal (median survival 3-5 months).14 The limitations of cytotoxic chemotherapy were evident.
The Molecular Revolution (2005–2017)
The turning point came from the understanding ATC pathogenesis. ATC often arises via dedifferentiation from pre-existing differentiated thyroid cancer (DTC). Landmark genomic studies (Landa et al., Kunstman et al.) revealed a complex mutational landscape.15,16 Key findings included:
These discoveries provided a rational basis for targeted therapy. Early trials of single-agent BRAF inhibitors (vemurafenib) or multikinase inhibitors (sorafenib, lenvatinib, pazopanib) showed modest, transient responses in ATC, but resistance was common.17,18 The rationale for combined BRAF and MEK inhibition emerged from melanoma studies to prevent paradoxical MAPK activation and delay resistance.
Table 1 lists most of the landmark studies which shaped the evolution of ATC management.
The Landmark Breakthrough: BRAF-Targeted Therapy (2018–Present)
The most important milestone in ATC history occurred in 2018 when the U.S. Food and Drug Administration (FDA) approved the combination of dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) for BRAF V600E-mutated ATC.19,20
Clinical Efficacy: The pivotal phase II ROAR trial (Subbiah et al., 2018) enrolled 16 patients with BRAF V600E-mutated ATC. The overall response rate (ORR) by independent review was 69% (including one complete response). The median progression-free survival (PFS) was 6.7 months, but the 12-month overall survival (OS) rate was an unprecedented 80%.19
Neoadjuvant Paradigm Shift: Subsequent studies demonstrated that this combination could rapidly shrink unresectable tumours, converting them to resectable. Wang et al. (2019) reported that after neoadjuvant dabrafenib/trametinib, 6 of 6 patients achieved complete R0/R1 resection, with 1-year OS of 83%.21 This has transformed surgical philosophy: systemic therapy now often precedes surgery in BRAF-mutant disease. Real-world experience confirms clinical trial results, with durable responses and manageable toxicities (fatigue, pyrexia, rash, nausea).22
Figure 2 summarises the targets and mechanisms of action of various drugs used in the management of ATC.
Emerging Roles: Immunotherapy and Other Targeted Agents [Table 2]
While BRAF-targeted therapy is transformative, it only benefits the ≈45% of ATC patients with the mutation. For BRAF-wildtype ATC, other approaches have emerged as salvage therapy.
Immune Checkpoint Inhibitors: ATCs frequently express high levels of PD-L1 (≈70-90%) and have an immune-rich but exhausted microenvironment. Single-agent anti-PD-1 therapy (Spartalizumab, Pembrolizumab) has shown ORRs of 19-29% in phase II trials, with durable responses in some patients.23 Preclinical and clinical data suggest synergy between kinase inhibitors and immunotherapy (e.g., Pembrolizumab added to dabrafenib/trametinib or lenvatinib).24,25
Other Actionable Targets:
Evolution of Supportive and Multidisciplinary Care
The modern management of ATC requires rapid, coordinated action by a multidisciplinary team (MDT): onco-surgeons, medical and radiation oncologists, endocrinologists, pathologists, and palliative care specialists. Early integration of palliative care is not "giving up" but rather optimising symptom control (pain, dyspnea, dysphagia), advance care planning, and supporting patients and families through a difficult journey.1 Ethical considerations, including goals of care, code status, and allow natural death orders, are discussed early. Figure 3 provides a graphical representation of the changes, and Table 3 compares therapeutic approaches across different eras.
Current Guidelines and Future Directions
The 2021 ATA guidelines29 and 2022 NCCN guidelines emphasize:
Figure 4 charts the current treatment algorithm in management of ATC. Future directions include overcoming acquired resistance to BRAF/MEK inhibitors (e.g., via PI3K pathway co-inhibition), optimizing immunotherapy combinations, developing antibody-drug conjugates, and utilising liquid biopsy for real-time monitoring.
CONCLUSION
The management of anaplastic thyroid carcinoma has undergone one of the most dramatic evolutions in modern oncology. From a uniformly fatal disease managed with palliative intent, ATC has become a potentially treatable condition for a subset of patients with actionable mutations, particularly BRAF V600E. The approval of dabrafenib plus trametinib represents the single most important therapeutic milestone, offering durable responses, enabling curative-intent surgery, and providing hope where there was none. While significant challenges remain, particularly for stage IVC and BRAF-wildtype disease, the continued integration of precision medicine, immunotherapy, and multidisciplinary care promises to further improve outcomes for patients with this historically devastating malignancy.
REFERENCES
Creative Commons License
Download PDF
Download XML